Betty Pettersen

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

Danna M. Breen, Hanna Kim, Donald Bennett et al. · Cell Metabolism · 2020 · 168 citations

Oncology, Weight Loss, Chemoprevention Strategy +10

Discovery of Two Clinical Histamine H ₃ Receptor Antagonists: <i>trans</i> - <i>N</i> -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and <i>trans</i> -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- <i>N</i> -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)

Travis T. Wager, Betty Pettersen, Anne W. Schmidt et al. · Journal of Medicinal Chemistry · 2011 · 107 citations · Full text

Discovery of the Potent and Selective M1 PAM-Agonist<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-Hydroxytetrahydro-2<i>H</i>-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

Jennifer E. Davoren, Che‐Wah Lee, Michelle R. Garnsey et al. · Journal of Medicinal Chemistry · 2016 · 83 citations · Full text

Design and Synthesis of γ- and δ-Lactam M₁ Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M₁-Selective PAM with Weak Agonist Activity

Jennifer E. Davoren, Michelle R. Garnsey, Betty Pettersen et al. · Journal of Medicinal Chemistry · 2017 · 58 citations · Full text

Identification of Multiple 5-HT₄Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

Michael A. Brodney, David E. Johnson, Aarti Sawant‐Basak et al. · Journal of Medicinal Chemistry · 2012 · 42 citations · Full text